HIV vaccine will be tested in South Africa at the end of this year after it will be checked and will meet the criteria required to help in the fight against the epidemic in Africa.
In 2015, there were 2.1 million new cases - two thirds of which occurred in Africa South of the Sahara. Small tested the vaccine, known as HVTN100 took place in South Africa in 2015, to test whether the vaccine to ensure the safety and strength of immunity of the affected population.
Two hundred fifty-two healthy volunteers were enrolled to receive the vaccine, known as ALVAC-HIV / gp120, to compare the degree of the generated immune response. The results were presented Tuesday at the 21st International AIDS conference in Durban, South Africa.
The vaccine stems from a landmark trial in Thailand in 2009, which was the first to show any protection from HIV infection protection 31% against the virus. That was enough to continue the experiments. The vaccine has been improved for use in populations at increased risk of Africa South of the Sahara, where there is also another subtype of the virus. Four criteria were established as a measure of its likely effectiveness, including the level of T-cell and humoral response against the virus.
More large-scale vaccine trials will now be held with 5.400 employees at four sites in South Africa in November 2016, for three years. The fifth dose of the vaccine will also be given in the hope of a more lasting effect protection.
Experts have long waits for vaccines showing enough efficiency in order to reduce the number of people who become infected with HIV, they fell by 0.7% between 2005 and 2015, according to a study published on Tuesday and presented at the conference.
sections: Society, World News